chr12:25362365:> Detail (hg19) (KRAS)

Information

Genome

Assembly Position
hg19 chr12:25,362,365-25,403,737
hg38 chr12:25,209,431-25,250,803 

HGVS

Type Transcript Protein
Summary

MGeND

Clinical significance
Variant entry
GWAS entry
Disease area statistics Show details

Frequency

[No Data.]

Prediction

[No Data.]

ClinVar

Clinical Significance
Review star [No Data.]
Show details
Links
Disease area statistics
[No Data.]
MGeND
[No Data.]
ClinVar
[No Data.]
CIViC
Disease Drug EL ET ED CS VO TR Pubmed Links
colorectal cancer Refametinib C Predictive Does Not Support Sensitivity/Response Somatic 2 23434733 Detail
pancreatic adenocarcinoma SCH772984,PI3Kbeta Inhibitor AZD8186 D Predictive Supports Sensitivity/Response Somatic 4 26725216 Detail
colorectal cancer Teprotumumab,Selumetinib D Predictive Supports Sensitivity/Response Somatic 3 21985784 Detail
colorectal cancer Bevacizumab,Chemotherapy B Predictive Supports Resistance Somatic 4 23828442 Detail
cancer MEK Inhibitor GDC-0623,G-573 D Predictive Supports Sensitivity/Response Somatic 3 23934108 Detail
colorectal cancer Ixazomib D Predictive Supports Resistance Somatic 1 26709701 Detail
cancer AZD5438 D Predictive Supports Sensitivity/Response Somatic 3 26881434 Detail
lung adenocarcinoma Salirasib B Predictive Does Not Support Sensitivity/Response Somatic 3 21847063 Detail
lung non-small cell carcinoma Trametinib B Predictive Supports Sensitivity/Response Somatic 2 22805291 Detail
pseudomyxoma peritonei B Prognostic Supports Poor Outcome Somatic 3 27502722 Detail
hepatocellular carcinoma Refametinib,Sorafenib B Predictive Supports Sensitivity/Response Somatic 2 25294897 Detail
lung adenocarcinoma B Prognostic Supports Poor Outcome Somatic 4 22810899 Detail
colorectal cancer Cetuximab D Predictive Supports Resistance Somatic 3 22586653 Detail
lung non-small cell carcinoma Gefitinib,Erlotinib B Predictive Supports Resistance Somatic 3 21258250 Detail
lung non-small cell carcinoma Selumetinib,Docetaxel A Predictive Supports Resistance Somatic 5 28492898 Detail
colorectal cancer Chemotherapy,Cetuximab B Predictive Supports Resistance Somatic 4 20619739 Detail
lung non-small cell carcinoma B Prognostic Supports Poor Outcome Somatic 3 21969500 Detail
lung non-small cell carcinoma Erlotinib B Predictive Supports Resistance Somatic 3 21969500 Detail
lung non-small cell carcinoma Abemaciclib B Predictive Supports Sensitivity/Response Somatic 3 27217383 Detail
lung non-small cell carcinoma Pemetrexed,Docetaxel,Trametinib B Predictive Supports Sensitivity/Response Somatic 3 27876675 Detail
lung non-small cell carcinoma Atezolizumab,Nivolumab B Predictive Supports Sensitivity/Response Somatic 3 28525386 Detail
lung non-small cell carcinoma A Predisposing Supports N/A N/A 5 28259530 Detail
colorectal cancer Selumetinib,Cetuximab B Predictive Does Not Support Sensitivity/Response Somatic 3 26666244 Detail
lung non-small cell carcinoma Trametinib B Predictive Does Not Support Sensitivity/Response Somatic 4 25722381 Detail
lung non-small cell carcinoma Selumetinib,Erlotinib B Predictive Does Not Support Sensitivity/Response Somatic 4 26802155 Detail
colorectal cancer Binimetinib,Palbociclib D Predictive Supports Sensitivity/Response Somatic 4 27167191 Detail
lung non-small cell carcinoma Docetaxel,Erlotinib B Predictive Does Not Support Sensitivity/Response Somatic 4 26209642 Detail
lung non-small cell carcinoma Docetaxel B Predictive Does Not Support Sensitivity/Response Somatic 4 20038723 Detail
colorectal cancer Panitumumab,Cetuximab A Predictive Supports Resistance Somatic 5 28275037 Detail
melanoma Vemurafenib,Dabrafenib B Predictive Supports Resistance Somatic 2 24265155 Detail
ovarian cancer Decitabine D Predictive Supports Sensitivity/Response Somatic 3 25968887 Detail
endometrial cancer Temsirolimus,Ridaforolimus B Predictive Does Not Support Sensitivity/Response Somatic 2 24166148 Detail
cancer Trametinib D Predictive Supports Sensitivity/Response Somatic 4 22169769 Detail
colorectal cancer Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitor,Immunomodulatory Oligonucleotide D Predictive Supports Sensitivity/Response Somatic 2 21890455 Detail
colorectal cancer Cetuximab,Dasatinib D Predictive Supports Sensitivity/Response Somatic 3 20956938 Detail
colorectal cancer B-Raf/VEGFR-2 Inhibitor RAF265,Selumetinib D Predictive Supports Sensitivity/Response Somatic 4 25199829 Detail
lung non-small cell carcinoma Selumetinib,B-Raf/VEGFR-2 Inhibitor RAF265 D Predictive Supports Sensitivity/Response Somatic 2 25199829 Detail
colorectal cancer Trametinib,Afatinib D Predictive Supports Sensitivity/Response Somatic 4 24685132 Detail
lung non-small cell carcinoma Trametinib,Afatinib D Predictive Supports Sensitivity/Response Somatic 2 24685132 Detail
lung non-small cell carcinoma MEK Inhibitor RO4987655 B Predictive Does Not Support N/A Somatic 1 24947927 Detail
colorectal cancer MEK Inhibitor RO4987655 B Predictive Does Not Support N/A Somatic 1 24947927 Detail
lung non-small cell carcinoma Docetaxel,Selumetinib B Predictive Supports Sensitivity/Response Somatic 4 23200175 Detail
DisGeNET
[No Data.]
Annotation

Annotations

DescrptionSourceLinks
Phase I trial of the mitogen-activated protein kinase 1/2 inhibitor BAY 86-9766. 4 patients with KRA... CIViC Evidence Detail
Inhibition of ERK in 11 KRAS mutant pancreatic cancer cell lines with SCH772984 was more effective t... CIViC Evidence Detail
Preclinial data from KRAS mutant colorectal cancer cell lines show syngergistic effect on cell viabi... CIViC Evidence Detail
Meta-Analysis of 12 studies with 2,266 patients (54 % were KRAS wt). The pooled response rates (RR) ... CIViC Evidence Detail
Preclinical study analyzing the differential response to MEK Inhibitors in KRAS and BRAF mutant canc... CIViC Evidence Detail
Preclinical study in colorectal cancer xenografts. KRAS-G13D or KRAS-G12V mutations were introduced ... CIViC Evidence Detail
CDK1 was identified in a preclinical siRNA screen to identify targets in KRAS mutant tumors. Cell vi... CIViC Evidence Detail
In a study of 30 lung adenocarcinoma patients with documented KRAS mutations, farnesylthiosalicylic ... CIViC Evidence Detail
In a phase 1 clinical trial for the use of trametinib for various advanced solid tumors, 22 out of 3... CIViC Evidence Detail
40 patients with pseudomyxoma peritonei underwent panel sequencing after cytoreductive surgery and h... CIViC Evidence Detail
Phase 2 study in Asian patients with unresectable hepatocellular carcinoma. 70 patients received ref... CIViC Evidence Detail
In a study of 1036 patients with lung adenocarcinoma, patients with KRAS mutations (n=241) showed wo... CIViC Evidence Detail
A cohort of patient-derived xenografts (PDX) from 85 patients with metastatic colorectal cancer was ... CIViC Evidence Detail
In a retrospective study, 166 non-small cell lung cancer (NSCLC) patients that tended to have select... CIViC Evidence Detail
A phase 3 study of selumetinib and docetaxel in KRAS mutant, previously treated NSCLC. 866 were enro... CIViC Evidence Detail
This was a retrospective study of 605 patients with metastatic, chemotherapy refractory colorectal c... CIViC Evidence Detail
Analysis was performed on the placebo group (n=451) of the Phase III study SATURN using erlotinib ma... CIViC Evidence Detail
In the placebo-controlled Phase III study SATURN, using erlotinib maintenance therapy for patients w... CIViC Evidence Detail
In this multicenter phase I study of abemaciclib, a total of 225 patients were enrolled: 33 in dose ... CIViC Evidence Detail
This phase I/Ib two-part study evaluated trametinib in combination with anticancer agents docetaxel ... CIViC Evidence Detail
A meta-analysis of randomized trials to investigate if KRAS mutation status affects survival benefit... CIViC Evidence Detail
In this meta-analysis of nine studies querying the association between KRAS status and PD-L1expressi... CIViC Evidence Detail
A phase I study to determine the tolerability and pharmacokinetics of Selumetinib and Cetuximab wit... CIViC Evidence Detail
In this phase II trial, trametinib or docetaxel was given to patients with advanced KRAS-mutant NSCL... CIViC Evidence Detail
38 KRAS wild-type patients were randomized to erlotinib or combination of selumetinib with erlotinib... CIViC Evidence Detail
A preclinical study to investigate the efficacy of Binimetinib, Palbociclib and the combination on K... CIViC Evidence Detail
222 EGFR-wt patients with advanced NSCLC were randomized to receive docetaxel or erlotinib In this s... CIViC Evidence Detail
Of the 275 patients assessable for KRAS mutation status, 49 (18%) were positive for KRAS mutation. T... CIViC Evidence Detail
NCCN guidelines indicate colorectal cancer patients with KRAS mutations should not be treated with t... CIViC Evidence Detail
In a retrospective study of 44 relapsed melanoma patients harboring BRAF V600E or V600K (known BRAF ... CIViC Evidence Detail
KRAS mutation or amplification predicted sensitivity to decitabine in ovarian cancer cell lines. The... CIViC Evidence Detail
94 endometrial cancer samples of women who had been treated with single agent mTOR inhibitors temsir... CIViC Evidence Detail
In this screen of 218 solid cancer cell lines, KRAS and BRAF mutations were predictive of response t... CIViC Evidence Detail
TLR9 agonist immunomodulatory oligonucleotide (IMO) led to inhibited survival of LS174T colorectal c... CIViC Evidence Detail
Combined treatment with dasatinib and cetuximab, but not either agent in monotherapy, had an antitum... CIViC Evidence Detail
SiRNA Screening in 37 KRAS Mutant colorectal cancer cell lines identified RAF1 and MEK Inhibition as... CIViC Evidence Detail
SiRNA Screening in 37 KRAS Mutant colorectal cancer cell lines identified RAF1 and MEK Inhibition as... CIViC Evidence Detail
An shDNA Screen identified synergy betwenn ERBB3 Inhibition and MEK Inhibition in KRAS mutated cell ... CIViC Evidence Detail
An shDNA screen identified synergy between ERBB3 Inhibition and MEK Inhibition in KRAS mutated cell ... CIViC Evidence Detail
Phase I expansion and pharmacodynamic study of the oral MEK inhibitor RO4987655 (CH4987655). 2 PR an... CIViC Evidence Detail
Phase I expansion and pharmacodynamic study of the oral MEK inhibitor RO4987655 (CH4987655). All 25 ... CIViC Evidence Detail
87 patients with KRAS mutant stage IIB-IV NSCLC after first line therapy were randomly assigned (1:1... CIViC Evidence Detail

Overlapped Transcript Coordinates

Gene Transcript ID Exon Number Chromosome Start Stop Type Amino Mutation Transcript Position Links

Overlapped Transcript

Gene Transcript ID Chromosome Start Stop Links
Gene
-
Genome
hg19
Position
chr12:25,362,365-25,403,737
Variant Type
snv
Variant (CIViC) (CIViC Variant)
MUTATION
Transcript 1 (CIViC Variant)
ENST00000256078.4
Variant URL (CIViC Variant)
https://civic.genome.wustl.edu/links/variants/336
Genome browser